MS

Merck KGaA's multiple sclerosis drug hit with partial FDA hold, adding to BTK-liver injury links
Fierce Biotech
Wed, 04/12/23 - 11:52 am
Merck KGaA
multiple sclerosis
MS
Btk inhibitors
liver damage
Immunic punts psoriasis, prostate cancer programs to narrow focus onto multiple sclerosis, celiac disease
Fierce Biotech
Thu, 04/6/23 - 10:01 am
Immunic
prostate cancer
psoriasis
MS
multiple sclerosis
celiac disease
Biogen gets EU court ruling in favor of blocking Tecfidera generic entry
Seeking Alpha
Thu, 03/16/23 - 09:44 am
Biogen
EMA
Europe
MS
multiple sclerosis
Tecfidera
generics
Roche sues Biogen over royalties related to multiple sclerosis drug Tysabri
Fierce Pharma
Wed, 03/1/23 - 07:08 pm
Roche
Genentech
patents
MS
multiple sclerosis
legal
Tysabri
Novartis loses $940M arbitration case against Mitsubishi Chemical over Gilenya royalties
Fierce Pharma
Mon, 02/20/23 - 12:42 pm
Novartis
Mitsubishi Chemical
multiple sclerosis
MS
Supreme Court
legal
patents
Gilenya
Novartis petitions Supreme Court in effort to 'vigorously defend' Gilenya patent
Endpoints
Tue, 01/24/23 - 06:18 pm
Novartis
Supreme Court
Gilenya
patents
generics
multiple sclerosis
MS
Roche’s Ocrevus Shines in Relapsing-Remitting MS, Safety Studies
BioSpace
Thu, 11/3/22 - 07:28 pm
Genentech
Roche
Ocrevus
MS
Relapsing Remitting Multiple Sclerosis
MS Drug Advances from Merck, BMS and More Showcased at ECTRIMS Conference
BioSpace
Wed, 10/26/22 - 06:51 pm
Merck
Biogen
Bristol Myers Squibb
MS
multiple sclerosis
ECTRIMS
ICER on MS drugs: TG's ublituximab not cost effective at the same price as Roche's ocrelizimab
Endpoints
Tue, 10/18/22 - 10:36 am
ICER
MS
multiple sclerosis
drug pricing
ublituximab
TG Therapeutics
Novartis' blockbuster Gilenya exposed to generics in short term amid Supreme Court appeal
Fierce Pharma
Fri, 10/14/22 - 10:40 am
Novartis
Gilenya
generics
Supreme Court
MS
multiple sclerosis
Facing 'imminent' Gilenya generics and a $300M sales hit, Novartis takes patent fight to Supreme Court
Fierce Pharma
Wed, 09/21/22 - 08:02 pm
Novartis
Supreme Court
Gilenya
patents
legal
MS
Unsealed documents detail Biogen's fight against Sandoz Tysabri biosimilar
Endpoints
Tue, 09/20/22 - 08:36 pm
Biogen
Novartis
Sandoz
biosimilars
Tysabri
MS
multiple sclerosis
BrainStorm Brings MS Data on Heels of ALS BLA Announcement
BioSpace
Fri, 09/16/22 - 10:19 am
BrainStorm Cell Therapeutics
NurOwn
multiple sclerosis
MS
Novartis dodges Gilenya kickback claims—again—after whistleblower lawsuit dismissed
Fierce Pharma
Wed, 09/14/22 - 08:04 pm
Novartis
whistleblowers
whistleblower lawsuit
Gilenya
kickbacks
MS
ACP and partners to launch Covid-19 vaccine study for multiple sclerosis
Clinical Trials Arena
Fri, 09/2/22 - 12:16 pm
Accelerated Cure Project
MS
multiple sclerosis
Quest Diagnostics
vaccines
clinical trials
COVID-19
Clene claims its PhII MS trial, half its intended size, cleared the primary goal. But can the biotech afford PhIII?
Endpoints
Mon, 08/15/22 - 10:23 am
Clene Nanomedicine
multiple sclerosis
MS
clinical trials
Biogen, watch out: Novartis' Tysabri biosim application could portend multiple sclerosis showdown in Europe and US
Fierce Pharma
Wed, 07/27/22 - 10:58 am
Novartis
Biogen
multiple sclerosis
MS
Tysabri
biosimilars
Novartis asks FDA to approve biosimilar for Biogen’s top-selling MS drug
BioPharma Dive
Mon, 07/25/22 - 09:54 pm
Novartis
FDA
Biogen
biosimilars
Tysabri
MS
multiple sclerosis
Biogen pays $900M to resolve whistleblower's MS kickback suit as competition drags on sales
Fierce Pharma
Wed, 07/20/22 - 11:17 pm
Biogen
whistleblowers
multiple sclerosis
MS
kickbacks
After ulcerative colitis flop, Immunic regains some momentum with multiple sclerosis update
Fierce Biotech
Wed, 06/15/22 - 10:58 am
Immunic
MS
multiple sclerosis
ulcerative colitis
vidofludimus calcium

Pages